Meningitis is associated with high morbidity and mortality in resource-rich and resource-limited settings \[[@CIT0001]\]. The human immunodeficiency virus (HIV) epidemic in sub-Saharan Africa (SSA) led to an increase in incidence of meningitis, especially in adults with advanced HIV disease \[[@CIT0002], [@CIT0003]\]. Case-fatality estimates for 3 of the main causes of adult meningitis in SSA---cryptoccoccal, pneumococcal, and tuberculous meningitis---range from 41% to 70%, and meningitis is the cause of up to 20% of deaths in HIV-infected cohorts \[[@CIT0004]\]. In addition to the high mortality, ongoing disability from neurological sequelae in survivors further increases the burden of disease due to meningitis \[[@CIT0007]\].

Multiple studies from Africa have reported neurological sequelae in pediatric survivors of meningitis \[[@CIT0008]\]. Pediatric studies show an increased risk of mortality from bacterial meningitis in HIV-infected versus uninfected children and greater risk of recurrence, suggesting that these patients are more susceptible to poor outcomes \[[@CIT0009], [@CIT0010]\]. However, the epidemiology and etiology of meningitis differs markedly between adults and children, and little is known about long-term outcomes of adult meningitis in Africa. From population-based estimates in rural Kenya, meningitis was one of the leading causes of disability-adjusted life years lost due to high case-fatality rates and long-term disability in HIV-uninfected survivors \[[@CIT0007]\]. A clear understanding of long-term disability of adult meningitis survivors in the context of the high regional burden of HIV-associated meningitis has important public health and economic implications for low- and middle-income countries \[[@CIT0006], [@CIT0011]\]. The aim of this systematic review is to describe our current understanding of neurologic sequelae in adult survivors of meningitis in Africa.

METHODS {#s1}
=======

Literature Search Strategy {#s2}
--------------------------

We conducted a systematic review of articles published on neurological sequelae of adult meningitis in Africa with no lower limit on start date until June 30, 2017. A search strategy was developed with 3 components: one identifying articles on "meningitis" or "meningoencephalitis," a second limiting the search to articles from Africa, and a third identifying articles reporting on neurological sequelae of disease. We searched 5 databases, including PubMed, Embase, Ovid, CENTRAL, and African Index Medicus. The full search strategy is shown in [Table 1](#T1){ref-type="table"}. Three reviewers (D. W. G., H. K. M., and M. W. T.) independently screened the databases using these search terms. We identified relevant supplemental articles through review of reference lists of relevant articles (published reviews and included studies) in the primary search. Citations were uploaded into an EndNote Library and duplicate articles were removed.

###### 

PubMed Search Terms

  -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Search component 1   \[meningitis OR meningoencephalitis\]
  Search component 2   \[Africa OR African OR Algeria OR Algerian OR Angola OR Angolan OR Benin OR Beninese OR Beninoise OR Botswana OR Botswanan OR Motswana OR Batswana OR Burkina Faso OR Burkinabe OR Burundi OR Burundian OR Cameroon OR Cameroonian OR cape Verde OR cape Verdean OR cab Verdeans OR central African republic OR central African OR chad OR Chadian OR Comoros OR Comorian OR democratic republic of the Congo OR Congolese OR republic of the Congo OR congo-brazzaville OR cote d'ivoire OR ivory coast OR Ivorian OR Ivoirian OR Djibouti OR Djiboutian OR Egypt OR Egyptian OR equatorial guinea OR equatorial guinean OR Equatoguinean OR Eritrea OR Eritrean OR Ethiopia OR Ethiopian OR Gabon OR Gabonese OR Gambia OR Gambian OR Ghana OR Ghanaian OR guinea OR Guinean OR Guinea- Bissau OR Bissau OR Kenya OR Kenyan OR Lesotho OR Basotho OR Mosotho OR Libya OR Libyan OR Madagascar OR Malagasy OR Malawi OR Malawian OR Mali OR Malian OR Mauritania OR Mauritanian OR Mauritius OR Mauritian OR Mayotte OR Mahuran OR morocco OR Moroccan OR Mozambique OR Mozambican OR Namibia OR Namibian OR Niger OR nigerien OR Nigeria OR Nigerian OR Rwanda OR Rwandan OR Rwandese OR Senegal OR Senegalese OR Seychelles OR Seychellois OR seychelloise OR sierra Leone OR sierra Leonean OR Somalia OR Somali OR south Africa OR south African OR Sudan OR Sudanese OR Swaziland OR Swazi OR Tanzania OR Tanzanian OR Togo OR Togolese OR Tunisia OR Tunisian OR Uganda OR Ugandan OR western Sahara OR western Saharan OR Zambia OR Zambian OR Zimbabwe OR Zimbabwean\]
  Search component 3   \[cognitive OR cognition OR neurocognitive OR neurocognition OR complications OR attention OR behavior OR behavioral OR behaviors OR sequelae OR impairment OR retardation OR epilepsy OR disorder OR learning OR memory OR function OR functions OR functional OR dysfunction OR dysfunctional OR dysfunctions OR deficit OR neuropsychological OR psychological OR psychomotor OR motor OR hyperactivity OR disability OR disabilities OR iq OR intelligence OR hearing OR sensorineural OR deaf OR deafness OR "rankin scale"\]
  -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Citation Screening (Inclusion/Exclusion Criteria) {#s3}
-------------------------------------------------

We screened citations against standardized eligibility criteria with initial title and abstract search followed by full text review of potentially eligible articles. Inclusion criteria included the following: (1) involving patients ≥12 years of age; (2) conducted at health centers in Africa; (3) reporting on prevalence or incidence of any neurologic sequelae in patients with meningitis; and (4) using a prospective or retrospective observational cohort methodology or randomized controlled trials. We excluded case studies and case series with less than 20 patients, because of concern for heterogeneity of reported outcomes and high likelihood of publication of nonrepresentative cases in case reports or case series, as well as published conference abstracts. For studies with pediatric and adult outcomes data separately reported, we excluded pediatric patients in our analysis. Adult and pediatric meningitis outcome data were intermixed in several included studies, primarily studies of *Neisseria meningitidis* meningitis. Inclusion of patients ≥12 years of age was decided as a developmentally meaningful cutoff (following rapid neurodevelopmental change, particularly in the first decade of life). We included studies reporting outcomes from microbiologically confirmed meningitis or meningitis diagnosed using molecular methods, and we also included studies with cases diagnosed using a combination of microbiological and/or molecular methods and cerebrospinal fluid (CSF) profiles suggestive of bacterial meningitis (CSF with polymorphonuclear cell pleocytosis), as well as *N meningitidis* diagnosed clinically during meningococcal meningitis epidemics. No language restrictions were placed on the search. Although no formal quality criteria were used to determine inclusion or exclusion of articles, we undertook a subjective assessment of trial quality based on established guidelines \[[@CIT0012]\].

Data Abstraction and Analysis {#s4}
-----------------------------

Study information was entered into Microsoft Excel spreadsheets, and accuracy was verified through consensus from all authors. Study year(s), country and clinical setting, study design, meningitis pathogen(s), patient clinical characteristics (age distribution and HIV status), follow-up period, outcomes measured, and outcomes data including both death and neurological sequelae were entered into spreadsheets ([Table 2](#T2){ref-type="table"} and [Table 3](#T3){ref-type="table"}). We categorized outcomes according to common sequelae, eg, hearing loss, as performed in previous meningitis reviews \[[@CIT0008], [@CIT0013]\]. Tables were organized by main causative pathogen and further sorted by year of publication.

###### 

Articles Included in Review

  Author, Publication Year \[Reference\]   Country, Setting, Year(s)                                                              Study Type                  Meningitis Type                                                                                                                                                                                                                                                                                                         Patient Assessed for Sequelae ±Death                             Sex Distribution, %Male (n/N)                      Age in Years, Mean (SD)[^\*^](#fn-01){ref-type="table-fn"}                                                       HIV Status, % (n/N)                                          Treatment Regimen                                                                                                                                                                                                                                                                                                                                                            Follow-Up                                                                                     Outcome Measures Recorded
  ---------------------------------------- -------------------------------------------------------------------------------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Neisseria meningitidis* Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Coldiron, 2016 \[[@CIT0045]\]            Niger, home visits, 2015                                                               Retrospective cohort        Of 194 CSF samples with positive PCR testing, identified *N meningitis* serogroup C (74%), serogroup W (19%) *Streptococcus pneumoniae* (6%), *N meningitidis* serogroup unspecified (1%)                                                                                                                               369                                                              60% (220 of 369)                                   Median 5--14[‡](#fn-03){ref-type="table-fn"}                                                                     NS                                                           Reported standard treatment ceftriaxone ×5 days                                                                                                                                                                                                                                                                                                                              Single evaluation 3.5--9 months after meningitis                                              Paralysis, anosmia, convulsions, hearing loss, loss of developmental milestones, persistent mental incapacity
  Jusot, 2013 \[[@CIT0046]\]               Niger, health facilities from 4 of 8 regions, 2010--2011                               Prospective cohort          *N meningitidis* serogroup W (87%), serogroup A (6%), and serogroup C (1%), *S pneumoniae* (6%)                                                                                                                                                                                                                         67                                                               53% (44 of 83)[†](#fn-02){ref-type="table-fn"}     13[‡](#fn-03){ref-type="table-fn"}                                                                               NS                                                           NS                                                                                                                                                                                                                                                                                                                                                                           Range 50--141 days                                                                            Functional symptoms, hearing loss, motor impairment, psychological troubles (using Conners' questionnaire)
  Seydi, 2002 \[[@CIT0020]\]               Senegal, referral hospital, 1999                                                       Prospective cohort          *N meningitidis* serogroup A (100%)                                                                                                                                                                                                                                                                                     70                                                               60% (42 of 70)                                     Median 20 (range 1--68)[‡](#fn-03){ref-type="table-fn"}                                                          NS                                                           Chloramphenicol 50 mg/kg IM daily in 3 doses ×8 days average (84%); cefotaxime 50 mg/kg IV daily ×5 days (9%); ceftriaxone 50 mg/ kg IM/IV daily ×5 days (7%)                                                                                                                                                                                                                In-hospital                                                                                   Hearing loss
  Hodgson, 2001 \[[@CIT0047]\]             Ghana, district hospital, 1999                                                         Prospective cohort          *N meningitidis* serogroup A                                                                                                                                                                                                                                                                                            505                                                              44% (225 of 505)                                   24 (15)[‡](#fn-03){ref-type="table-fn"}                                                                          NS                                                           NS                                                                                                                                                                                                                                                                                                                                                                           Surviving patients evaluated 2 years after outbreak                                           Cerebellar disorder, cranial nerve palsy, hydrocephalus, motor deficit
  Heyman, 1998 \[[@CIT0025]\]              Zaire (Democratic Republic of Congo), refugee field hospital, 1994                     Retrospective cohort        Bacterial meningitis during *N meningitis* epidemic (included cases confirmed by CSF positive for Gram-negative diplococci, culture, or soluble antigen test OR based on clinical picture and turbid CSF)                                                                                                               45                                                               48% (25 of 52)[†](#fn-02){ref-type="table-fn"}     13 (standard error of the mean 1)[‡](#fn-03){ref-type="table-fn"}                                                12% (2 of 17)                                                Penicillin 4 million units IV 6 times/day + chloramphenicol 1 gram 4 times/ day (29 of 37 \[78%\] patients with records); chloramphenicol (6 of 37 \[16%\]); penicillin (1 of 37) \[3%\]; ciprofloxacin (1 of 37 \[3%\])                                                                                                                                                     In-hospital                                                                                   Clinically obvious neurological damage
  Fekade, 1992 \[[@CIT0048]\]              Ethiopia, referral hospital, 1988                                                      Prospective cohort          Bacterial meningitis (CSF with polymorphonuclear cell pleocytosis, low glucose, and high protein OR positive Gram stain OR bacterial culture OR clinical presentation consistent with *N meningitis*); all presumed *N meningitidis* (serogroup A)                                                                      204                                                              64% (179 of 278)[†](#fn-02){ref-type="table-fn"}   Range 15--49; 57% in age group 15--19[†](#fn-02){ref-type="table-fn"}                                            NS                                                           Penicillin-based therapy (80%); Combination penicillin and chloramphenicol (20%); treatment duration 7--10 days                                                                                                                                                                                                                                                              In-hospital                                                                                   Cranial nerve palsy, deafness, hemiplegia
  Girgis, 1989 \[[@CIT0018]\]              Egypt, referral hospital and US Navy research unit, 1983-NS                            Prospective unblinded RCT   *N meningitidis* (62%), *S pneumoniae* (25%), *Haemophilus influenzae* (13%)                                                                                                                                                                                                                                            429                                                              65% (278 of 429)                                   14 (9) in group treated with dexamethasone; 13 (9) in control group[‡](#fn-03){ref-type="table-fn"}              NS                                                           Ampicillin 160 mg/kg IV daily in 4 doses + chloramphenicol 100 mg/ kg IV daily in 4 doses ×8 days ±dexamethasone 12 mg IV every 12 hours ×3 days                                                                                                                                                                                                                             Monthly ×6 months                                                                             Hearing loss, hemiparesis
  Smith, 1988 \[[@CIT0049]\]               Gambia, outpatient therapy, 1982--1983                                                 Prospective cohort          Presumed *N meningitidis* serogroup A during epidemic; 15.3% (25 of 157) bacteriologically confirmed by CSF or blood culture with most cases diagnosed clinically                                                                                                                                                       157                                                              50% (78 of 157)                                    Median 10--14[‡](#fn-03){ref-type="table-fn"}                                                                    NS                                                           Chloramphenicol 3 grams IM once                                                                                                                                                                                                                                                                                                                                              6--12 months                                                                                  Generalized sequelae (irritability/poor cooperation, slow response, mental retardation, severe brain damage), coordination impairment, cranial nerve palsy, hearing loss, motor deficit, visual loss
  Habib, 1979 \[[@CIT0016]\]               Egypt, referral hospital and US Navy research unit, 1966--1973                         Prospective cohort          *N meningitidis* (100%)                                                                                                                                                                                                                                                                                                 375 (≥10 years)                                                  56% (438 of 775)[†](#fn-02){ref-type="table-fn"}   ≥10 years; 73% in age group 10--19[‡](#fn-03){ref-type="table-fn"}                                               N/A                                                          NS                                                                                                                                                                                                                                                                                                                                                                           Monthly ×6 months                                                                             Hearing loss
  *Streptococcus pneumoniae* Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Ajdukiewicz, 2011 \[[@CIT0022]\]         Malawi, referral hospital, 2006--2008                                                  Prospective RCT             Bacterial meningitis (CSF with \>100 white cells/μL with polymorphonuclear cell predominance or cloudy CSF); 41% confirmed *S pneumoniae* and 42% overall confirmed bacterial                                                                                                                                           125[§](#fn-04){ref-type="table-fn"}                              48% (61 of 128)[†](#fn-02){ref-type="table-fn"}    Median 32 (IQR, 27--38)[†](#fn-02){ref-type="table-fn"}                                                          84% (104 of 124)                                             Ceftriaxone 2 grams IV twice daily ×minimum 10 days                                                                                                                                                                                                                                                                                                                          40 days                                                                                       Hearing loss, neurological disability by Glasgow Outcome Score
  Manga, 2008 \[[@CIT0021]\]               Senegal, referral hospital, 1995--2004                                                 Retrospective cohort        *S pneumoniae* (100%)                                                                                                                                                                                                                                                                                                   73                                                               67% (49 of 73)                                     44 (19.5)                                                                                                        12% (9 of 73)                                                Ampicillin or amoxicillin 200 mg/kg IV daily in 3 doses; cefotaxime 100--200 mg/kg IV 3 times daily; ceftriaxone 50--75 mg/kg IV daily; gentamicin 3 mg/kg IV daily with a β-lactam; chloramphenicol 100 mg/ kg IV daily                                                                                                                                                     In-hospital                                                                                   Deafness, facial palsy, hemiparesis, oculomotor paralysis
  Scarborough, 2007 \[[@CIT0023]\]         Malawi, referral hospital, 2002--2005                                                  Prospective RCT             Bacterial meningitis (CSF with \>100 white cells/μL or cloudy CSF); *S pneumoniae* (56%), *N meningitidis* (4%), other Gram-negative organism (6%), other (1%)                                                                                                                                                          465                                                              49% (230 of 465)                                   32 (11)                                                                                                          90% (389 of 434)                                             Ceftriaxone 2 grams IV/IM twice daily ×10 days ±dexamethasone 16 mg IV twice daily ×4 days                                                                                                                                                                                                                                                                                   40 days                                                                                       Blindness, debility, hearing loss, intellectual impairment, paresis, seizure disorder
  Okome-Nkoumou, 1999 \[[@CIT0026]\]       Gabon, referral hospital, 1991--1995                                                   Retrospective cohort        *S pneumoniae* (65%), *N meningitidis* (29%), *Escherichia coli* (4%), *Pseudomonas aeruginosa* (2%)                                                                                                                                                                                                                    85                                                               71% (60 of 85)                                     Median 33 (range 16--60)                                                                                         18% (15 of 85)                                               Amoxicillin/clavulanate 12 grams IV daily ×15 days (19%); cefotaxime 6 grams IV daily ×10 days (56%); cefotaxime 6 grams IV daily + dexamethasone 0.5 mg IV twice daily ×10 days (25%)                                                                                                                                                                                       In-hospital                                                                                   Deafness
  Ford, 1994 \[[@CIT0027]\]                Swaziland, national report system at 4 district hospitals, 1991--1992                  Prospective cohort          Bacterial meningitis (CSF with \>1000 white cells/mm^3^, \>75% polymorphonuclear cells, glucose \<1.9 mmol/L, and protein \>1 g/L, or positive Gram stain OR bacterial culture); in larger cohort of 85 patients (including children), *S pneumoniae* (29%), *N meningitidis* (12%), *H influenzae* (9%), others (9%)   24 adults (≥15 years)                                            NS                                                 ≥15 (no further break-down)                                                                                      12% (3 of 24) with known HIV (likely significantly higher)   Benzyl-penicillin 4 million units IV every 4 hours + chloramphenicol 25 mg/kg IV every 6 hours ×7--10 days                                                                                                                                                                                                                                                                   In-hospital                                                                                   Ataxia, confusion, cranial nerve palsy, deafness, developmental delay, hemiparesis, hydrocephalus, seizure disorder, confusion
  Other/Mixed Bacterial Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  El-Gindy, 2015 \[[@CIT0028]\]            Egypt, fever hospital, 2013--2015                                                      Prospective cohort          Confirmed bacterial meningitis (positive CSF stain and/or culture); including 26% (16 of 61) tuberculous meningitis; 74% (45 of 61) other bacterial meningitis, including *S pneumoniae* (40%), *N meningitidis* (20%), *H influenzae* (22%), *S aureus* (13%), *E coli* (4%)                                           61 adults (≥16 years                                             69% (42 of 61)                                     61% (37 of 61) 16--40, 24% (15 of 61) 41--60, 15% (9 of 61) ≥61                                                  NS                                                           NS                                                                                                                                                                                                                                                                                                                                                                           In-hospital                                                                                   Mini-Mental status exam (MMSE), Wechsler Memory Scale (WMS), Glasgow Outcome Scale (GOS), cranial nerve palsy, ischemic brain insult, seizures, speech disorders, hydrocephalus
  Hammad, 2011 \[[@CIT0017]\]              Egypt, referral hospital and US Navy research unit, 1993--2009                         Retrospective cohort        All gram-negative bacilli; *E coli* (25%), *Proteus mirabilis* (22%), *P aeruginosa* (17%), *Salmonella typhi* (17%), *Klebsiella pneumoniae* (14%), *Enterobacter* spp (5%)                                                                                                                                            95                                                               64% (61 of 95)                                     13 (6) in cases of primary meningitis; 32 (8) in cases of secondary meningitis[‡](#fn-03){ref-type="table-fn"}   NS                                                           Ceftriaxone 3 grams IV daily ×10 days + dexamethasone 0.2 mg/kg IV ×3 days                                                                                                                                                                                                                                                                                                   In-hospital                                                                                   Cerebral damage, hearing loss, hemiplegia, hydrocephalus, optic atrophy, seizure disorder
  TB Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Marais, 2013 \[[@CIT0033]\]              South Africa, referral hospital, 2009--2010                                            Prospective cohort          Tuberculous meningitis (both "definite" cases with CSF acid-fast stain positive and/or culture positive AND "probable" cases with clinical, laboratory, and radiographic features in absence of other diagnosis)                                                                                                        34                                                               56% (19 of 34)                                     Median 33 (IQR, 29--44)                                                                                          100% (34 of 34); all antiretroviral naive                    Antituberculous therapy given according to national guidelines with prednisone 1.5 mg/kg PO daily × 6 weeks then prednisone 0.75 mg/ kg PO daily × 2 weeks (unless TB-IRIS); antiretroviral therapy initiated at 2 weeks                                                                                                                                                     2, 4, 6, and 12 weeks, 6 months, 9 months                                                     Marked cognitive impairment by International HIV Dementia Scale, hemiparesis, hearing loss
  Girgis, 1998 \[[@CIT0019]\]              Egypt, referral hospital and US Navy research unit, 1976--1996                         Prospective cohort          Tuberculous meningitis (100% culture-confirmed)                                                                                                                                                                                                                                                                         857                                                              58% (497 of 857)                                   17 (13)[‡](#fn-03){ref-type="table-fn"}                                                                          NS (all patients who received HIV testing were negative)     *P*-aminosalicylic acid + isoniazid + streptomycin; ethambutol + isoniazid + streptomycin; ethambutol + isoniazid + streptomycin ± dexamethasone; rifampin + isoniazid + streptomycin; all patients treated for 2 years                                                                                                                                                      Eye exam weekly ×6 months during hospital stay then monthly outpatient visits up to 2 years   Cerebral atrophy, cranial nerve palsy, fundus changes, hemiparesis-paraplegia, hydrocephalus
  Cryptococcal Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Montgomery, 2017 \[[@CIT0032]\]          Uganda, referral hospital, 2010--2012                                                  Prospective RCT             Cryptococcal meningitis (100%)                                                                                                                                                                                                                                                                                          90                                                               60% (54 of 90)                                     Median 36 (IQR, 30--40)                                                                                          100% (90 of 90)                                              Amphotericin B 0.7--1.0 mg/kg IV daily + fluconazole 800 mg PO daily ×2 weeks; then fluconazole 800 mg PO daily ×3 weeks; then fluconazole 400 mg PO daily ×8 weeks; then fluconazole 200 mg PO daily; antiretroviral therapy initiated at 5 weeks; participants randomized to early (1--2 weeks after diagnosis) or late (5 weeks after diagnosis) antiretroviral therapy   Single evaluation 1 month after meningitis diagnosis                                          Battery of neuropsychological tests evaluating 8 domains; calculated quantitative neurocognitive performance score (QNPZ-8) as mean of individual z-scores and compared with age- and education-adjusted scores of HIV-uninfected Ugandans; also tested Karnofsky, International HIV Dementia Scale, and Center for Epidemiologic Studies Depression (CES-D) Scale scores
  Beardsley, 2016 \[[@CIT0030]\]           Malawi, Uganda, Indonesia, Laos, Thailand, Indonesia, referral hospitals, 2013--2014   Prospective RCT             Cryptococcal meningitis (100%)                                                                                                                                                                                                                                                                                          226 (excluding patients treated with adjunctive dexamethasone)   58% (132 of 226)                                   Median 35 (IQR, 30--40)                                                                                          100% (226 of 226)                                            Amphotericin B 1.0 mg/kg IV daily + fluconazole 800 mg PO daily ×2 weeks; then fluconazole 800 mg PO daily ×8 weeks; then fluconazole 200 mg PO daily; antiretroviral therapy initiated at 5 weeks                                                                                                                                                                           10 weeks and 6 months                                                                         Visual acuity at 10 weeks, level of disability at 10 weeks and 6 months (assessed by combination of modified Rankin scale and 2 questions \[does the patient require help from anybody for everyday activities, and has the illness left the patient with any other problems?\])
  Carlson, 2014 \[[@CIT0029]\]             Uganda, referral hospital, 2010--2013                                                  Prospective cohort          Cryptococcal meningitis (100%)                                                                                                                                                                                                                                                                                          78                                                               62% (48 of 78)                                     35 (8)                                                                                                           100% (78 of 78)                                              Amphotericin B 0.7--1.0 mg/kg IV daily + fluconazole 800 mg PO daily ×2 weeks; then fluconazole 800 mg PO daily ×3 weeks; then fluconazole 400 mg PO daily ×8 weeks; then fluconazole 200 mg PO daily; antiretroviral therapy initiated at 5 weeks                                                                                                                           1, 3, 6, and 12 months                                                                        Battery of neuropsychological tests evaluating 8 domains; calculated quantitative neurocognitive performance score (QNPZ-8) as mean of individual z-scores and compared with age- and education-adjusted scores of HIV-uninfected Ugandans
  Rothe, 2013 \[[@CIT0024]\]               Malawi, referral hospital, 2010--2011                                                  Prospective cohort          Cryptococcal meningitis (100%)                                                                                                                                                                                                                                                                                          60                                                               55% (33 of 60)                                     Median 32 (IQ,R 29--39)                                                                                          100% (60 of 60)                                              Fluconazole 800 mg PO ×2 weeks; then fluconazole 400 mg PO daily ×6 weeks; then fluconazole 200 mg PO daily; antiretroviral therapy initiated at 4 weeks                                                                                                                                                                                                                     4 weeks, 10 weeks, 52 weeks                                                                   Neurological function tested at 52 weeks by modified Rankin Scale score and Abbreviated Mental Test Score

Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IM, intramuscular; IV, intravenous; IQR, interquartile range; N/A, not applicable; NS, not stated; OR, odds ratio; PCR, polymerase chain reaction; PO, per os (oral); RCT, randomized controlled trial; SD, standard deviation; TB-IRIS, tuberculosis-associated immune reconstitution inflammatory syndrome.

Unless otherwise stated.

Included additional patients lost to follow up, not included, or without outcomes data.

Included some pediatric patients (\<12 years).

Excluded intervention arm receiving glycerol, which was associated with significantly higher mortality and disability.

No formal meta-analysis was undertaken due to the small number of studies meeting inclusion criteria as well as heterogeneity in causative pathogen, follow-up period, and neurological sequelae evaluated. Descriptive statistics were used to analyze outcomes using percentage, median and interquartile range, mean and standard deviation, or other descriptive measures as indicated. We did not report pooled neurological sequelae of individual studies due to significant heterogeneity in types of sequelae evaluated, method of sequelae evaluation between studies, and limited number of studies for most major causative pathogens.

RESULTS {#s5}
=======

Literature Search and Citation Screening {#s6}
----------------------------------------

The search yielded 6204 original articles for review on June 30, 2017. The database was deduplicated, and then a primary screen by article title was executed ([Figure 1](#F1){ref-type="fig"}); 3241 articles were excluded at this point. Most references were screened out because they contained data in neonatal and/or pediatric populations or described case studies or small case series. A secondary screening of full abstracts was then conducted in which a further 943 articles were excluded for not including data on neurological outcomes. In articles that did not include abstracts, we reviewed full-text articles. Three additional review articles were identified, and relevant references from these reviews were included in the final article list \[[@CIT0008], [@CIT0014], [@CIT0015]\]. Full text of the remaining 380 articles was obtained and each article was reviewed. Of these, 22 met all inclusion criteria and were included in the final review.

![Diagram of literature search.](ofx24601){#F1}

Articles in the Review {#s7}
----------------------

We identified 22 articles meeting inclusion criteria with 12 African countries represented ([Figure 2](#F2){ref-type="fig"}). In all but 1 study, patients were treated for meningitis in hospital settings, with treatment provided at referral centers in 17 studies. The only or predominate cause of meningitis was nontuberculous bacterial in 16 studies, *Mycobacterium tuberculosis* in 2 studies, and *Cryptococcus* in 4 studies.

![Origin of studies included in review and estimated human immunodeficiency virus prevalence.](ofx24602){#F2}

Four studies were published at a single referral hospital/US Navy research unit in Egypt \[[@CIT0016]\] and 2 at a single referral hospital in Senegal \[[@CIT0020], [@CIT0021]\], both countries with a low HIV prevalence. Three studies were published from a single large referral hospital in Malawi with predominately HIV-infected patients (84%--100% HIV prevalence) \[[@CIT0022]\]. Follow-up duration was variable: 8 of the 22 studies presented only in-hospital neurological sequelae of survivors, and follow-up for the remaining 14 studies ranged from 1 month to 2 years. Twelve articles were prospective cohort studies, 5 were retrospective cohort studies, and 5 were prospective randomized-controlled trials (RCTs) \[[Table 2](#T2){ref-type="table"}\].

*Neisseria meningitidis* Meningitis {#s8}
-----------------------------------

*Neisseria meningitidis* was the principle pathogen identified in 9 bacterial studies with 2718 patients. *Neisseria meningitidis* was the only pathogen isolated from 6 studies. Penicillin or ampicillin and/or chloramphenicol were used to treat patients in most studies. Only 1 study \[[@CIT0025]\] gave any information on HIV serostatus and reported low prevalence. Follow-up ranged from in-hospital to a 2-year follow-up of survivors. Males constituted 56% (1529 of 2718) of patients ([Table 2](#T2){ref-type="table"}).

Ascertainment of adult outcomes was imperfect because most (8 of 9) studies included both adult and pediatric patients without separation by age category. Mortality data were included in 5 studies and ranged from 3% to 21% (median 13%). In meningitis survivors, hearing loss (8 studies) and motor deficits (5 studies) were the most commonly reported neurological sequelae. Any hearing loss was found in 2%--31% of patients (median 5%) with severe/profound hearing loss reported in 2%--10% of patients (median 3%). Motor deficits were variably defined and ranged from 1% to 13% (median 2%) in 5 studies with moderate-to-severe disability (eg, hemiplegia/hemiparesis) in 1%--2% (median 2%) from 3 studies. One study reported 6% of patients with moderate-to-severe visual loss and 3% with moderate-to-severe neurocognitive deficit at evaluation 6 to 12 months after the meningitis episode ([Table 3](#T3){ref-type="table"}).

###### 

Results Including Death and Neurological Complications From Included Articles

  Author, Publication Year \[Reference\]                             Follow-Up Period                                     Pathogen(s) Studied                                                                   %Died (n/N)                                                                                                                       %Visual Deficit (n/N)                                               %Hearing Deficit (n/N)                                                           %Neurocognitive Dysfunction (n/N)                                                                                                                                                                                                                                                                %Motor Deficit (n/N)[^\*^](#fn-05){ref-type="table-fn"}                        %Seizure Disorder (n/N)                           %Other Outcomes (n/N)
  ------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Neisseria meningitidis* meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Coldiron, 2016 \[[@CIT0045]\]                                      Single evaluation 3.5--9 months after meningitis     *N meningitidis* primary pathogen identified (94% of CSF samples with positive PCR)   17% (64 of 369) of patient households with home visits; 12% (23 of 189) of patients with confirmed *N meningitidis* serogroup C                                                                       12% (15 of 126) of patients any confirmed pathogen had any hearing loss          3% (4 of 126) with any confirmed pathogen had persistent mental incapacity or loss of milestones                                                                                                                                                                                                                                                                                                                                  11% (33 of 305) of surviving patients, including 15% (19 of 126) with confirmed *N meningitidis* serogroup C had any sequellae reported
  Jusot, 2013 \[[@CIT0046]\]                                         Range 50--141 days                                   *N meningitidis* (94%)                                                                N/A                                                                                                                                                                                                   31% (21 of 67) any hearing loss; 10% (7 of 67) severe hearing loss                                                                                                                                                                                                                                                                                                                12% (8 of 65) walking or tonus impairment                                                                                        Asthenia 37% (24 of 65); headache 31% (21 of 67); psychological troubles 16%; vertigo 22% (15 of 67)
  Seydi, 2002 [@CIT0020]                                             In-hospital                                          *N meningitidis*                                                                      3% (3 of 73)                                                                                                                                                                                          3% (2 of 71) deaf                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Hodgson, 2001 \[[@CIT0047]\]                                       2 years                                              *N meningitidis*                                                                      N/A                                                                                                                                                                                                   6% (32 of 496) any hearing loss; 2% (8 of 496) severe hearing loss                                                                                                                                                                                                                                                                                                                1% (3 of 505) decreased motor strength                                                                                           Hydrocephalus 0% (0 of 505); hyperreflexia of upper limbs 15% (78 of 505)
  Heyman, 1998 \[[@CIT0025]\]                                        In-hospital                                          *N meningitidis*                                                                      13% (6 of 45)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Residual neurological damage 5% (2 of 39)
  Fekade, 1992 \[[@CIT0048]\]                                        In-hospital                                          Mostly *N meningitidis*                                                               21% (43 of 204)                                                                                                                                                                                       2% (3 of 161) deaf                                                                                                                                                                                                                                                                                                                                                                2% (4 of 161) hemiplegia                                                                                                         Cranial nerve palsy 2% (3 of 161)
  Girgis, 1989 \[[@CIT0018]\]                                        Monthly ×6 months                                    Majority *N meningitidis* (62%)                                                       14% (62 of 429) \[lower case fatality rate in steroid group\]                                                                                                                                         3% (9 of 367) severe hearing loss                                                                                                                                                                                                                                                                                                                                                 1% (3 of 367) hemiparesis (all in patients with *N meningitidis* infection)                                                      
  Smith, 1988 \[[@CIT0049]\]                                         6--12 months                                         *N meningitidis*                                                                      N/A                                                                                                                               23% (23 of 102) any visual loss; 6% (6 of 102) moderate-to-severe   6% (9 of 155) any sensorineural hearing loss; 4% (6 of 155) severe-to-profound   17% (27 of 156) any; 3% (5 of 156) moderate-to-severe                                                                                                                                                                                                                                            13% (21 of 156) at least mild motor defect; 2% (3 of 156) moderate-to-severe                                                     Coordination impairment 11% (17 of 155); cranial nerve palsy 9% (14 of 155)
  Habib, 1979 \[[@CIT0016]\]                                         Monthly ×6 months                                    *N meningitidis*                                                                      N/A                                                                                                                                                                                                   4% (16 of 375) any hearing loss; 2% (7 of 375) deaf                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  *Streptococcus pneumoniae* Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Ajdukiewicz, 2011 \[[@CIT0022]\]                                   40 days                                              *S pneumoniae* (41% confirmed)                                                        49% (61 of 125); 39% (20 of 51) with proven *S pneumoniae*                                                                                                                                            34% (14 of 41) deaf                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Persistent vegetative state 22% (14 of 63)
  Manga, 2008 \[[@CIT0021]\]                                         In-hospital                                          *S pneumoniae* (100%)                                                                 70% (51 of 73)                                                                                                                                                                                        4% (1 of 22) deaf                                                                                                                                                                                                                                                                                                                                                                 32% (7 of 22) motor deficit of extremity                                                                                         Cranial nerve palsy 23% (5 of 22)
  Scarborough, 2007 \[[@CIT0023]\]                                   40 days                                              Majority *S pneumoniae* (56%)                                                         54% (249 of 459); 51% (140 of 272) proven *S pneumoniae*                                                                          3% (7 of 202) blind                                                 34% (66 of 195) any hearing loss; 12% (24 of 195) severe hearing loss            6% (13 of 202)                                                                                                                                                                                                                                                                                   8% (17 of 202)                                                                 1% (2 of 202)                                     Debility 5% (10 of 202)
  Okome-Nkoumou, 1999 \[[@CIT0026]\]                                 In-hospital                                          Majority *S pneumoniae* (65%)                                                         17% (15 of 85)                                                                                                                                                                                        3% (2 of 70) hearing loss                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Ford, 1994 \[[@CIT0027]\]                                          In-hospital                                          *S pneumoniae* (29%) most common isolate                                              62% (15 of 24)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Any neurological sequelae in 33% (3 of 9)
  Other Bacterial Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  El-Gindy 2015 \[[@CIT0028]\]                                       In-hospital                                          Mix confirmed bacterial meningitis pathogens and tuberculous meningitis               33% (20 of 61); 31% (5 of 16) with tuberculous meningitis and 33% (15 of 45) with bacterial meningitis                                                                                                                                                                                 Bacterial meningitis 13% (4 of 30) severe impairment by MMSE and 30--47% impairment in WMS domains; tuberculous meningitis 27% (3 of 11) severe impairment by MMSE and 18--54% impairment in WMS domains                                                                                                                                                                        Bacterial meningitis 3% (1 of 30) with seizures   Bacterial meningitis 23% (7 of 30) cranial nerve palsy, 33% (10 of 30) ischemic brain insult, 3% (1 of 30) speech disorder, and 43% (13 of 30) survivors with severe disability by GOS; tuberculous meningitis 9% (1 of 11) cranial nerve palsy, 54% (6 of 11) ischemic brain insult, 9% (1 of 11) hydrocephalus, and 45% (5 of 11) survivors with severe disability by GOS score
  Hammad, 2011 \[[@CIT0017]\]                                        In-hospital                                          Gram-negative bacilli                                                                 29% (28 of 95)                                                                                                                    9% (6 of 67) optic atrophy                                          6% (4 of 67) hearing loss                                                                                                                                                                                                                                                                                                                                                         7% (5 of 67) hemiplegia                                                        7% (5 of 67)                                      Cerebral damage 1% (1 of 67); hydrocephalus 7% (5 of 67)
  TB Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Marais, 2013 \[[@CIT0033]\]                                        2, 4, 6, and 12 weeks, 6 months, 9 months            *Mycobacterium tuberculosis*                                                          12% (4 of 34)                                                                                                                                                                                         3% (1 of 30) hearing loss                                                        20% (6 of 30) cognitive impairment                                                                                                                                                                                                                                                               7% (2 of 30) hemiparesis                                                                                                         
  Girgis, 1998 \[[@CIT0019]\]                                        Once weekly ×6 months then monthly through 2 years   *M tuberculosis*                                                                      57% (490 of 857)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        5% (20 of 367) hemiparesis/hemiplegia                                                                                            Cerebral atrophy 3% (11 of 367); cranial nerve palsy 5% (20 of 367); fundus changes 8% (30 of 367); hydrocephalus 8% (30 of 367)
  Cryptococcal Meningitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Montgomery, 2017 \[[@CIT0032]\] [‡](#fn-07){ref-type="table-fn"}   1 month after HIV diagnosis                          *Cryptococcus neoformans*                                                             N/A                                                                                                                                                                                                                                                                                    92% with International HIV Dementia Scale score ≤10 (indicative of possible HIV-associated neurocognitive disorder) compared with 66% of HIV-infected controls without meningitis; mean QNPC-8 z-score −2.22 (referenced against age- and education-adjusted, HIV-negative Ugandan population)                                                                                                                                    Median Karnofsky score 60 (IQR, 50--70); higher rates of depression than HIV-infected controls without meningitis (median CES-D score 23 \[IQR, 16--30\] and 9 \[IQR, 5--17\], respectively)
  Beardsley, 2016 \[[@CIT0030]\]                                     10 weeks and 6 months                                *C neoformans*                                                                        48% (109 of 226) at 6 months                                                                                                      4% (5 of 127) decreased visual acuity at 10 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      36% (46 of 127) survivors with intermediate and 20% (26 of 127) with severe disability at 10 weeks; 30% (34 of 114) with intermediate and 10% (12 of 114) with severe disability at 6 months
  Carlson, 2014 \[[@CIT0029]\] [‡](#fn-07){ref-type="table-fn"}      1, 3, 6, and 12 months                               *C neoformans*                                                                        12% (9 of 78)[†](#fn-06){ref-type="table-fn"}                                                                                                                                                                                                                                          89% (69 of 78) with composite z-score \< −1 at 1 month, 59% (41 of 69) at 3 months, 47% (32 of 68) at 6 months, and 41% (26 of 64) at 12 months                                                                                                                                                                                                                                                                                   Inability to work at 12 months 11% (7 of 62)
  Rothe, 2013 \[[@CIT0024]\]                                         4 weeks, 10 weeks, 52 weeks                          *C neoformans*                                                                        72% (43 of 60) at 12 months; additional 4 patients lost to follow-up                                                                                                                                                                                                                   0% (0 of 6) tested at 52 weeks had significant disability by modified Rankin Scale score and Abbreviated Mental Test Score                                                                                                                                                                                                                                                                                                        

Abbreviations: CSF, cerebrospinal fluid; CES-D, Center for Epidemiologic Studies Depression; GOS, Glasgow Outcome Scale; HIV, human immunodeficiency virus; IQR, interquartile range; MMSE, Mini-Mental Status Exam; N/A, not applicable; PCR, polymearse chain reaction; RCT, randomized controlled trial; TB, tuberculosis; WMS, Wechsler Memory Scale.

Included hemiparesis, hemiplegia, unspecified motor deficit in category.

Overall 6-month mortality in study 38% (67 of 177).

Included outcomes of patients from the same prospective RCT.

*Steptococcus pneumoniae* and Other Bacterial Meningitides {#s9}
----------------------------------------------------------

Five studies including 772 patients reported on neurological outcomes with *Streptococcus pneumoniae* as the single or most commonly confirmed pathogen. *Streptococcus pneumoniae* was the only pathogen in 1 study \[[@CIT0021]\], was identified in 65% of cases in 1 study limited to microbiologically confirmed cases \[[@CIT0026]\], and was isolated in 29%--56% of cases from 3 studies with a large percentage of cases diagnosed by CSF cellular profile \[[@CIT0022], [@CIT0023], [@CIT0027]\]. Treatment differed between studies, and adjunctive dexamethasone was used for a subgroup of patients in only 2 studies \[[@CIT0023], [@CIT0026]\]. Human immunodeficiency virus prevalence was high across studies, between 12% and 90%. Follow-up ranged from in-hospital to 40 days. Males constituted 53% (400 of 751) of cases ([Table 2](#T2){ref-type="table"}).

Two prospective RCTs from Malawi of primarily HIV-infected adult patients were high quality with the remaining studies of relatively poor quality \[[@CIT0022], [@CIT0023]\]. Reported case-fatality rate ranged from 17% to 70% (median 54%). In the 2 Malawian prospective RCTs with mostly HIV-infected adults, mortality ranged from 49% to 54% overall and 39% to 51% in cases of proven pneumococcal meningitis, all managed with ceftriaxone (±dexamethasone). Hearing loss was reported to affect 3%--34% (median 19%) of patients in 4 studies, with severe/profound hearing loss reported in 4%--34% (median 12%) of patients in 3 studies. Motor deficits were reported at 8%--32% in 2 studies, with no other outcome documented in more than a single study ([Table 3](#T3){ref-type="table"}).

The 2 Malawian studies with predominately HIV-infected patients reported high rates of neurological sequelae in survivors \[[@CIT0022], [@CIT0023]\]. In Ajdukiewicz et al \[[@CIT0022]\], 22% (14 of 63) survivors, with or without pneumococcal disease, remained in a persistent vegetative state (Glasgow Outcome Score 2) at 40 days. In Scarborough et al \[[@CIT0023]\], 23% (47 of 202) of 40-day survivors and 29% (38 of 130) of those with proven pneumococcal meningitis had 1 or more neurological sequelae (blindness, debility, complete deafness, intellectual impairment, paresis, or recurrent seizures).

One retrospective cohort study from Egypt evaluated neurological sequelae in 95 patients with microbiologically confirmed, Gram-negative, bacillary meningitis \[[@CIT0017]\]. This study included both adults and children and did not include data on HIV status. The case-fatality rate was 29% (28 of 95), and the rate of pooled in-hospital sequelae (cerebral damage, hearing loss, hemiplegia, hydrocephalus, optic atrophy, and/or seizure disorder) in survivors was 39% (26 of 67). Six percent (4 of 67) of survivors had hearing loss, 7% (5 of 67) had hemiplegia, 7% (5 of 67) had seizure disorder, and 9% (6 of 67) had optic atrophy. Another study from Egypt included patients with a mix of microbiologically confirmed bacterial meningitis and tuberculous meningitis \[[@CIT0028]\]. At hospital discharge, 43% (13 of 30) of survivors with bacterial meningitis and 45% (5 of 11) with tuberculous meningitis had severe disability determined by Glasgow Outcomes Scale score.

Cryptococcal Meningitis {#s10}
-----------------------

Four articles evaluated neurological sequelae of HIV-infected adult patients with cryptococcal meningitis \[[@CIT0024], [@CIT0029]\]. One good-quality study from Uganda reported global neurocognitive dysfunction, defined as mean composite score of multidomain neurocognitive testing at least 1 standard deviation below that of HIV-uninfected Ugandans (z-score \< −1), serially over 1 year in cryptococcal meningitis survivors who received amphotericin-based induction therapy. At 1 month, 89% (69 of 78) of survivors had impaired neurocognitive function. This improved to 41% (26 of 64) at 1 year \[[@CIT0029]\]. Meningitis survivors had only slightly higher disability compared with HIV-infected Ugandans without a prior history of neurological infection. The case-fatality rate for patients who lived to 1 month was 12% (9 of 78) at 1 year; 5 of those patients died before a 1-month follow up, and 3 patients died before the 6-month follow up. A second study from the same prospective RCT reported additional 1-month neurocognitive outcomes \[[@CIT0032]\]. At 1 month, 92% of survivors had an International HIV Dementia Scale score ≤10, suggesting possible HIV-associated neurocognitive disorder. Six-month neurocognitive outcomes from another quality large prospective RCT found that 20% of survivors had severe disability at 10 weeks and 10% at 6 months, defined as answering yes to the question "Does the patient require help from anybody for everyday activities?" or with a Modified Rankin Scale score of ≥3 (symptoms that restrict lifestyle and prevent totally independent living) \[[@CIT0030]\]. Of note, this study included patients from countries in both Africa (Malawi and Uganda) and Asian countries, but neurocognitive outcomes were not disaggregated by country. We also excluded patients receiving experimental dexamethasone therapy, which was associated with higher rates of mortality and other adverse outcomes and is not part of the usual treatment.

Tuberculosis Meningitis {#s11}
-----------------------

We included 2 articles with 891 patients with sequelae data for tuberculosis meningitis. One high-quality but small study with 34 antiretroviral therapy (ART)-naive HIV-infected adults with tuberculous meningitis (confirmed or suspected) evaluated patients for tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) after ART initiation. The case-fatality rate was 12% (4 of 34) at 9 months, with all deaths occurring in patients with TB-IRIS at time points of 33, 53, 60, and 118 days after tuberculous meningitis diagnosis. Of 9-month survivors, 20% (6 of 30) had marked disability: 20% (6 of 30) cognitive impairment (5 of 6 marked impairment defined as HIV dementia scale score \<10), 7% (2 of 30) hemiparesis, and 3% (1 of 30) hearing loss \[[@CIT0033]\]. A second study from a referral hospital in Egypt reported outcomes in a large cohort of patients treated for tuberculous meningitis over 2 decades (1976--1996) \[[@CIT0019]\]. This study included adults and children together, and no patients were known to be HIV-infected. Patients received 3-drug antituberculous therapy for 2 years, during which period they were serially assessed for neurological sequelae. In total, 57% (490 of 857) of patients died and 30% (111 of 367) of patients survived with severe neurological sequelae (including cranial nerve palsy 5% \[20 of 367\], hemiparesis-paraplegia 5% \[20 of 367\], and hydrocephalus 8% \[30 of 367\]).

DISCUSSION {#s12}
==========

In our systematic review of neurological sequelae of adult meningitis in Africa, we identified 22 articles with neurological sequelae outcome data in meningitis survivors. This included 12 studies in counties with high HIV prevalence. These studies, published over a more than 35-year period, provide limited data showing high rates of postmeningitis disability in adult meningitis survivors from resource-limited settings, particularly in those with HIV coinfection. More importantly, they reveal the paucity of high-quality data regarding the frequency and spectrum of neurological sequelae after adult meningitis from prospective studies, and they provide insight into gaps in our current understanding of long-term disability of adult meningitis survivors. Accurate data regarding the long-term outcomes in adult meningitis survivors are essential for accurate estimates of disease burden and, given the frequency of adult meningitis in Africa, have broad public health and economic implications.

Our review highlights that little is known about long-term neurological sequelae in survivors of HIV-associated cryptococcal meningitis and tuberculous meningitis, 2 of the principle causes of adult meningitis in sub-Saharan Africa. Two articles included Ugandan patients from a single prospective RCT \[[@CIT0029], [@CIT0032]\]. As in prior studies in the region, acute mortality was high at 38% by 26 weeks of follow up \[[@CIT0004], [@CIT0034]\]. These studies found significant impairment in the early weeks after incident cryptococcal meningitis, with Montgomery et al \[[@CIT0032]\] reporting 92% of survivors with an International AIDS Dementia Scale score suggestive of neurocognitive impairment, compared with 66% of HIV-infected controls without meningitis. With longer follow-up, Carlson et al \[[@CIT0029]\] reported persistent neurocognitive deficits in approximately half of survivors at 1 year. The relationship between this long-term neurocognitive impairment and cryptococcal meningitis remains unclear. Although cryptococcal meningitis survivors also showed worse neurocognitive function compared with HIV-infected Ugandans, these differences were small by 1 year of follow-up, and the control patients generally had less advanced HIV disease (mostly stage II and III) \[[@CIT0029]\]. Neurocognitive deficits may have been a consequence of meningitis and/or other contributing factors, such as HIV-associated neurocognitive disorder \[[@CIT0039], [@CIT0040]\]. The choice of comparator also limits inferential reasoning and could be strengthened in this and other studies evaluating neurocognitive domains with alternative comparator groups, such as HIV-infected populations started early on ART. A second multicountry prospective RCT conducted in African and Asian countries found that 20% and 10% of survivors reported requiring help with everyday activities at 10 weeks and 6 months, respectively \[[@CIT0030]\]. Taken together, these data suggest significant impairment early after incident cryptococcal meningitis, a period during which adherence to ART and continuation of fluconazole maintenance therapy are critical to prevent cryptococcal meningitis relapse and for overall survival.

Five studies described neurological sequelae in adult meningitis with *S pneumoniae*, the most common cause of bacterial meningitis in HIV-infected adults, as the predominate pathogen \[[@CIT0002], [@CIT0041]\]. Two of these studies \[[@CIT0022], [@CIT0023]\], both from Malawi, consisted largely of HIV-infected adults and found approximately half of patients died of meningitis with one quarter of survivors left with severe disability, such as with persistent vegetative states or hemiparesis. These adverse outcomes are significantly higher than rates of death and disability reported in resource-rich countries with low HIV prevalence, but they are more reflective of African pediatric populations \[[@CIT0008], [@CIT0014]\]. These data also likely underestimated the impact of pneumococcal meningitis in HIV-infected African cohorts because patients were enrolled in controlled clinical trials at a large referral hospital and given highly effective antibiotic therapy with ceftriaxone. Because follow up was limited to 40 days, they may also have underestimated delayed outcomes such as epilepsy \[[@CIT0042]\]. Unfortunately, in Africa, pneumococcal vaccination has demonstrated mixed efficacy for reducing invasive pneumococcal disease, and dexamethasone therapy has not been associated with lower mortality or neurological sequelae in HIV-infected adults \[[@CIT0023], [@CIT0043], [@CIT0044]\]. The best method for reduction in risk of incident disease and associated neurological sequelae is early HIV recognition and initiation of ART coupled with timely and appropriate antibiotic therapy \[[@CIT0041]\].

Our review has several important limitations. First, case definitions, outcome measures, and means of assessment were highly variable between studies. A lack of validated neurocognitive and limited neurological function assessments created very heterogeneous data and prevented formal meta-analysis. Second, follow-up periods differed considerably with only approximately half of studies reporting outcomes after hospital discharge to characterize clinical evolution of disease. Third, because there were few studies evaluating outcomes in cryptococcal and tuberculous meningitis, no firm conclusions could be drawn about neurological outcomes in survivors but rather emphasizes the need for future studies, especially prospective cohort studies, to include multidomain measures of neurological outcomes of disease. Finally, for most studies involving meningococcal meningitis, neurological sequelae of pediatric and adult cases were not reported separately, which limited our ability to make firm conclusions about adult outcomes. In this mixed population, however, death and disability was significantly lower than in cases of pneumococcal meningitis, as reported elsewhere \[[@CIT0014]\].

CONCLUSIONS {#s13}
===========

In conclusion, although settings with high HIV prevalence in Africa have both a high incidence of meningitis and early mortality, long-term sequelae in adult survivors remains poorly characterized. Limited data suggest high rates of neurological disability associated with HIV-related pneumococcal and TB meningitis. Little is known about neurological sequelae in survivors of HIV-associated cryptococcal meningitis, although studies suggest extremely high prevalence of neurocognitive and functional impairment in the early weeks after incident disease. Furthermore, long-term multidomain testing of neurological outcomes for survivors of HIV-associated cryptococcal meningitis and TB meningitis is warranted. Tools need to be chosen carefully and consider challenges with repeat testing, such as risk of learner bias.

There is a need for improved understanding of neurological sequelae of adult meningitis in Africa. Pneumococcal meningitis in the setting of high HIV prevalence confers a high risk of both death and severe neurological sequelae in survivors. Little is published on sequelae from HIV-associated cryptococcal or tuberculous meningitis, highlighting an urgent need to more accurately define outcomes of survivors in future studies.
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